

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/623,039-Conf. #1401
				Filing Date	July 18, 2003
				First Named Inventor	Subhashis BANERJEE
				Art Unit	1643
				Examiner Name	D. J. Blanchard
Sheet	1	of	2	Attorney Docket Number	117813-18707

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US 2009-0280065 A1	11-12-2009	Willian et al.	
	A2	US 2010-0040604 A1	02-18-2010	Salfeld et al.	
	A3	US 2010-0034823 A1	02-11-2010	Borhani et al.	
	A4	US 2009-0148513 A	06-11-2009	Fraunhofer et al.	
	A5	7,588,761	09-15-2009	Salfeld et al.	
	A6	US 2010-0016557 A1	01-21-2010	Salfeld et al.	
	A7	US 2009-0155205 A1	06-18-2009	Salfeld et al.	
	A8	US 2009-0304682 A1	12-10-2009	Hoffman et al.	
	A9	US 2010-0160894 A1	06-24-2010	Julian et al.	
	A10	US 2009-0291062 A1	11-26-2009	Fraunhofer et al.	
	A11	US 2009-0317399 A1	12-24-2009	Pollack et al.	
	A12	US 2010-0021451 A1	01-28-2010	Wong et al.	
	A13	US 2010-0003243 A1	01-07-2010	Okun et al.	
	A14	US 2009-0258018 A1	10-15-2009	Medich et al.	
	A15	US 2009-0239259 A1	09-24-2009	Hsieh et al.	
	A16	US 2009-0226530 A1	09-10-2009	Lassner et al.	
	A17	US 2009-0271164 A1	10-29-2009	Peng et al.	
	A18	US 2010-0040630 A1	02-18-2010	Elden et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Corluy, L. "Clinical Response Compared to DAS28 and ACR-Response Criteria in Rheumatoid Arthritis Patients on Infliximab." Abstract of presentation at the EULAR conference. (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/623,039-Conf. #1401
				Filing Date	July 18, 2003
				First Named Inventor	Subhashis BANERJEE
				Art Unit	1643
				Examiner Name	D. J. Blanchard
Sheet	2	of	2	Attorney Docket Number	117813-18707

C2	Mease, P. J., "Adalimumab: an anti-TNF agent of the treatment of psoriatic arthritis" Expert Opinion Biol Ther 5(11): 1491-1504 (2005)	
C3	Ruperto, N. "48-Week Data From the Study of Adalimumab in Children With Juvenile Rheumatoid Arthritis (JRA)" Ann. Rheum. Dis. 65 (Suppl II):56 (2006)	
C4	Genovese, M. <i>et al.</i> "Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy" Ann Rheum Dis 64(Suppl III): 313 [FRI0187] (2005)	
C5	Kavanaugh, A. <i>et al.</i> "Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: results from ADEPT" Ann Rheum Dis 64(Suppl III): 325 [FRI0227] (2005)	
C6	Gordon, K. <i>et al.</i> "Clinical Response to Adalimumab Treatment in Patients with Moderate to Severe psoriasis: Double-Blind, Randomized Controlled Trial and Open-Label Extension Study." J. Am. Acad. Derm. 55(1):598-606 (2006)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.